ArticleOncology reports2021
Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth
Article in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Bioactive plant and fungal metabolites in oral cancer: molecular mechanisms and translational potential.Frontiers in pharmacology · 2026Review
- Therapeutic potential of green tea's epigallocatechin-3-gallate in oral cancer: a comprehensive systematic review of cellular and molecular pathways.Discover oncology · 2025Article
- Natural anti-cancer products: insights from herbal medicine.Chinese medicine · 2025Review
- Oxidative Stress and Dietary Antioxidants in Head and Neck Cancer.Antioxidants (Basel, Switzerland) · 2025Review
- Prominent Naturally Derived Oxidative-Stress-Targeting Drugs and Their Applications in Cancer Treatment.Antioxidants (Basel, Switzerland) · 2025Review
- Molecular Evidence of the Bio-activities of Traditional Home Medicine Ingredients.Current topics in medicinal chemistry · 2025Review
- Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives.Cancer prevention research (Philadelphia, Pa.) · 2024Review
- Effects of Green Tea Extract Epigallocatechin-3-Gallate on Oral Diseases: A Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Natural Products for Cancer Prevention and Interception: Preclinical and Clinical Studies and Funding Opportunities.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Chemopreventive and Biological Strategies in the Management of Oral Potentially Malignant and Malignant Disorders.Bioengineering (Basel, Switzerland) · 2024Review
- Dietary Polyphenols against Oxidative Stress in Head and Neck Cancer: What's New, What's Next.Journal of Cancer · 2024Review
- The combined anticancer of peanut skin procyanidins and resveratrol to CACO-2 colorectal cancer cells.Food science & nutrition · 2023Article
- Article
- What nature has to offer: Opportunities for immuno-oncology.Journal of food and drug analysis · 2023Review
- Article
- Review
- Combination Anticancer Therapies Using Selected Phytochemicals.Molecules (Basel, Switzerland) · 2022Review
- Plants as a Source of Anticancer Agents: From Bench to Bedside.Molecules (Basel, Switzerland) · 2022Review
- Resveratrol, EGCG and Vitamins Modulate Activated T Lymphocytes.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Despite widespread interest in chemoprevention and therapy due to the high margin of safety of dietary natural compounds, clinical intervention with single agents has failed to yield the expected outcomes, mostly due to poor bioavailability and low potency. Combinations of natural agents with synergistic effects are gaining increasing attention. In the present study,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.